https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50456 2 cm (4.5%) or grade 3 tumors (5.5%). These sustained reductions of the risk of recurrence with adjuvant exemestane + OFS, compared with tamoxifen + OFS, provide guidance for selecting patients for whom exemestane should be preferred over tamoxifen in the setting of OFS.]]> Wed 28 Feb 2024 15:10:42 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50457 Wed 28 Feb 2024 15:09:41 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50584 Wed 28 Feb 2024 15:06:35 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:37935 Wed 14 Jul 2021 09:23:23 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47165 2) was categorized as follows: 18.5 to < 25, lean; 25 to < 30, overweight; and ≥ 30, obese. Disease-free survival (DFS) was the primary endpoint, and overall survival (OS) was the secondary endpoint. A second-order interaction was assessed among treatment, BMI, and estrogen receptor (ER) status. Results: There was no difference in DFS or OS according to BMI in the non-docetaxel group, while reduced DFS and OS were observed with increasing BMI category in the docetaxel group. Adjusted hazard ratios for DFS and OS were, respectively, 1.12 (95% CI, 0.98 to 1.50; P = .21) and 1.27 (95% CI, 1.01 to 1.60; P = .04) for overweight versus lean groups and were 1.32 (95% CI, 1.08 to 1.62; P = .007) and 1.63 (95% CI, 1.27 to 2.09; P < .001), respectively, for obese versus lean groups. Similar results were obtained when considering ER-negative and ER-positive tumors separately and when considering only patients who received a relative dose intensity ≥ 85% for docetaxel. A joint modifying role of BMI and ER status on treatment effect was evident for DFS (adjusted P = .06) and OS (adjusted P = .04). Conclusion: This retrospective analysis of a large adjuvant trial highlights a differential response to docetaxel according to BMI, which calls for a body composition–based re-evaluation of the risk-benefit ratio of the use of taxanes in breast cancer. These results now must be confirmed in additional series.]]> Wed 14 Dec 2022 15:49:14 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:22946 Wed 11 Apr 2018 16:42:13 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:29519 .05). In both treatment arms, we observed significant trends for lower adherence with increasing severity for all symptoms (P < .01) except headaches (P = .054). Conclusion: In the IBIS-I trial, experiencing predefined symptoms in the first 6 months reduced long-term adherence. Effects were similar between treatment arms, suggesting that women were attributing age-related symptoms to preventive therapy. Interventions were required to support symptom management.]]> Wed 11 Apr 2018 12:50:17 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:24890 Wed 09 Feb 2022 15:54:09 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:31072 v standard], 0.96; 90% CI, 0.77 to 1.2). Ten deaths as a result of prostate cancer occurred in the short arm and 12 in the standard arm. No significant differences were detected between arms for grade ≥ 3 late genitourinary and GI toxicity. Conclusion: The hypofractionated RT regimen used in this trial was not inferior to conventional RT and was not associated with increased late toxicity. Hypofractionated RT is more convenient for patients and should be considered for intermediate-risk prostate cancer.]]> Wed 02 Mar 2022 14:26:55 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:23224 Thu 04 Nov 2021 10:40:21 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:24426 Thu 04 Nov 2021 10:39:39 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:7568 Sat 24 Mar 2018 08:42:03 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:7958 Sat 24 Mar 2018 08:34:56 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:995 Sat 24 Mar 2018 08:29:49 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:989 Sat 24 Mar 2018 08:29:49 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:13280 Sat 24 Mar 2018 08:15:16 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:13279 Sat 24 Mar 2018 08:15:16 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:13278 2 twice daily for 14 of every 21 days; n = 107) or continuously (650 mg/m² twice daily for 21 of every 21 days; n = 107), or to classical CMF (oral cyclophosphamide 100 mg/m² days 1 to 14 with intravenous methotrexate 40 mg/m² and fluorouracil 600 mg/m² on days 1 and 8 every 28 days; n = 109). The primary end point was quality-adjusted progression-free survival (PFS); secondary end points included PFS, overall survival (OS), objective tumor response, and adverse events. Intermittent and continuous capecitabine were to be compared first and, if similar (P > .05), combined for definitive comparisons versus CMF. Results: Quality-adjusted PFS (P = .2), objective tumor response rate (20%; P = .8), and PFS (median, 6 months; hazard ratio [HR], 0.86; 95% CI, 0.67 to 1.10; P = .2) were similar in women assigned capecitabine versus CMF. OS was longer in women assigned capecitabine rather than CMF (median, 22 v 18 months; HR, 0.72; 95% CI, 0.55 to 0.94; P = .02). Febrile neutropenia, infection, stomatitis, and serious adverse events were more common with CMF; hand-foot syndrome was more common with capecitabine. Conclusion: Capecitabine improved OS by being similarly active, less toxic, and more tolerable than CMF. Capecitabine is a good first-line chemotherapy option for women with advanced breast cancer who are unsuited to more intensive regimens.]]> Sat 24 Mar 2018 08:15:16 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:11280 35 kg/m2) at baseline had more recurrences than those women with a low BMI (BMI < 23 kg/m2; adjusted hazard ratio [HR], 1.39; 95% CI, 1.06 to 1.82; Pheterogeneity = .03) and significantly more distant recurrences (adjusted HR, 1.46; 95% CI, 1.07 to 1.61; Pheterogeneity = .01). Overall, the relative benefit of anastrozole versus tamoxifen was nonsignificantly better in thin women compared to overweight women. Conclusion: These results confirm the poorer prognosis of obese women with early-stage breast cancer. Recurrence rates were lower for anastrozole than tamoxifen for all BMI quintiles. Our results suggest that the relative efficacy of anastrozole compared to tamoxifen is greater in thin postmenopausal women and higher doses or more complete inhibitors might be more effective in overweight women, but this requires independent confirmation.]]> Sat 24 Mar 2018 08:12:44 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:11225 Sat 24 Mar 2018 08:11:14 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:11170 Sat 24 Mar 2018 08:10:42 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:10494 Sat 24 Mar 2018 08:08:58 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:21393 = 30 kg/m²) had slightly poorer OS (hazard ratio [HR] = 1.19; 95% CI, 0.99 to 1.44) than patients with normal BMI (< 25 kg/m²), whereas no trend in OS was observed in overweight (BMI 25 to < 30 kg/m²) versus normal-weight patients (HR = 1.02; 95% CI, 0.86 to 1.20). Treatment-by-BMI interactions were not statistically significant. The HRs for OS comparing obese versus normal BMI were HR = 1.22 (95% CI, 0.93 to 1.60) and HR = 1.18 (95% CI, 0.91 to 1.52) in the letrozole and tamoxifen groups, respectively. Conclusion: There was no evidence that the benefit of letrozole over tamoxifen differed according to patients' BMI.]]> Sat 24 Mar 2018 08:05:04 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:17517 Sat 24 Mar 2018 08:03:50 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:17404 Sat 24 Mar 2018 08:01:40 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:20093 Sat 24 Mar 2018 08:00:06 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:17720 Sat 24 Mar 2018 07:57:26 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:17755 Sat 24 Mar 2018 07:57:21 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:20038 Sat 24 Mar 2018 07:50:54 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:5453 Sat 24 Mar 2018 07:48:12 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:5450 Sat 24 Mar 2018 07:48:10 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:5271 Sat 24 Mar 2018 07:46:32 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:5363 Sat 24 Mar 2018 07:43:57 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:26262 Sat 24 Mar 2018 07:40:14 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:29413 Sat 24 Mar 2018 07:36:21 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:29414 Sat 24 Mar 2018 07:36:12 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:29018 P = .14) and in triple-negative (TN) disease (n = 814; HR, 0.80; 95% CI, 0.60 to 1.06). Patients with TN, node-positive disease had a nonstatistically significant reduced HR (n = 340; HR, 0.72; 95% CI, 0.49 to 1.05). Seventy-one (13%) of 542 patients assigned to CM maintenance did not start CM. Of 473 patients who received at least one CM maintenance dose (including two patients assigned to no CM), 64 (14%) experienced a grade 3 or 4 treatment-related adverse event; elevated serum transaminases was the most frequently reported (7%), followed by leukopenia (2%). Conclusion: CM maintenance did not produce a significant reduction in DFS events in hormone receptor-negative early breast cancer. The trend toward benefit observed in the TN, node-positive subgroup supports additional exploration of this strategy in the TN, higher-risk population.]]> Sat 24 Mar 2018 07:31:09 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:22087 Sat 24 Mar 2018 07:15:16 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:23759 Sat 24 Mar 2018 07:11:09 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:23220 Sat 24 Mar 2018 07:10:38 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:22368 Sat 24 Mar 2018 07:09:30 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:22369 Sat 24 Mar 2018 07:09:29 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:44162 Mon 10 Oct 2022 10:07:08 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:43006 Fri 09 Sep 2022 14:17:25 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:23758 Fri 05 Mar 2021 18:51:52 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:30333 Fri 01 Apr 2022 09:24:55 AEDT ]]>